Rayno Life Science Stocks Move Higher: CLVS, RHHBY-ASCO Preview
Rayno Biopharmaceutical Stocks– ASCO Plays or Not Large Caps Rule Clovis Oncology (CLVS) up 16.7%, 79% YTD to $100 level! Several data CLVS Presentations for ASCO including two oral and six posters for non-small cell lung cancer and ovarian cancer. Also with a valuation of only $3.4B and...
Hot Biotech Sector: Mid-Caps Have Both M&A and Pipeline Premiums
Valuations Step-Up With More Deals Prior to the acquisition of Pharmacyclics (PCYC) by Abbvie (ABBV) for $20B, the top price paid for an emerging biotech company was in the $10B range. Two additional companies among the mid-caps were acquired in prior years: Cubist by Merck in December 2014...
Biotechs Tag Along With Broad Market Rally: FBT Up 3%
Jobs Report Drive Stocks Higher-DOW Up 1.5% Stocks moved higher on the “goldilocks” job report which showed a gain of 223k added in April. The jobs number was too high to raise concerns about an increase in rates but not too bullish because overall productivity is down. Jobless...
M&A Sparks Biotechs: Alexion Buys Syngeva for $8.4B…Update-1
Orphan Drugs-The Latest Hot Spot in Biotech Large Cap Biotechs Were Red-Specualtive Stocks Were Green XBI 214.9 up 2.36% GEVA $203.4 up 112% NASDAQ 4919 down 0.4% Rare Disease Companies Merge: ALXN and GEVA Alexion Pharmaceuticals (ALXN) the leading company in severe and life threatening...
Surveying the Damage with Rayno Life Science Stocks…2015 YTD
Biotech Bounce-Caution on New Positions IBB up 2% at 340 support level Most biotech stocks are green as of early trading on May 1. Although the sector has taken a beating since April 23 most ETFs and funds are outperforming the market year to date up more than 10%. As we posted earlier this...